Abstract
The LEADER and SUSTAIN-6 cardiovascular (CV) outcome trials demonstrated CV risk reduction for liraglutide and semaglutide in patients with type 2 diabetes (T2D). We analysed post hoc the impact of diabetes duration on cardiorenal efficacy of these GLP-1 analogs. LEADER and SUSTAIN-6 randomized
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
